AR032569A1 - Ligandos del receptor de canabinoide - Google Patents
Ligandos del receptor de canabinoideInfo
- Publication number
- AR032569A1 AR032569A1 ARP020100423A ARP020100423A AR032569A1 AR 032569 A1 AR032569 A1 AR 032569A1 AR P020100423 A ARP020100423 A AR P020100423A AR P020100423 A ARP020100423 A AR P020100423A AR 032569 A1 AR032569 A1 AR 032569A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- aryl
- heteroaryl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C31/18—Polyhydroxylic acyclic alcohols
- C07C31/24—Tetrahydroxylic alcohols, e.g. pentaerythritol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/41—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/42—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
Abstract
Se describen compuestos de la formula (1), una de sus prodrogas, o una sal, un solvato o un esteroisomero aceptable para uso farmacéutico del compuesto o de dicha prodroga; que exhiben actividad antiinflamatoria inmunomoduladora. Además, se describen composiciones farmacéuticas que contienen dichos compuestos y métodos de uso de los compuestos para el tratamiento de varias enfermedades condiciones, donde arilalquilo, heterocicloalquilo, heteroarilo, N(R2)2, o NR2arilo, arilo no sustituido o arilo sustituido con uno a tres X; R2 es igual o diferente en cada caso y se selecciona en forma independiente de H o alquilo de C1-6; R3 es H, alquilo de C1-6, Cl, F; CF3, OCF2H, OCF3, OH o alcoxi de C1-6; R4 es H, alquilo de C1-6, alcoxi de C1-6, cicloalquilo, alquenilo, arilo, bencilo, heteroarilo, heterocicloalquilo, NH-arilo, NH-heteroarilo, NH-cicloalquilo, N(R2)2 o NR2arilo, dicho alquilo, alcoxi, cicloalquilo, alquenilo, fenilo o heteroarilo se sustituyen en forma opcional con uno a tres X; R5 es H o alquilo de C1-6; R6 es H o alquilo de C1-6; R5 y R6 juntos con el átomo de carbono forman un grupo carbonilo; L1 es alquileno de C1-6, alquenilo de C2-6, (C(R2)2), >C=O, -CHOR2-, -NOR2-, -SO2-, -SO-, -S-, -O-, -N(R2)2-, -C(O)NR2-, -NR2C(O)-, -CHCF3- o -CF2- >C=O; L2 es un enlace covalente, alquileno de C1-6, -C(R2)2-, -CHOR2-, C(R2)OH, -NOR2-, -SO2-, -NR2SO2, -SO-, -S-, -O-, -SO2NR2-, -N(R2)-, -C(O)NR2-, o -NR2C(O)-; X es igual o diferente y se selecciona en forma independiente de H, halogeno, CF3, CN, OCF2H, OCF2CF3, OCF3, OR2, alquilo de C1-6, cicloalquilo, cicloalcoxi, alcoxi de C1-6, alcoxi de C1-6alcoxi, O-cicloalquilo, cicloalquilamino, cicloalquilalcoxi, heteroarilo, OSO2R2, COOR2, CON(R2)2, NHR2, NH-arilo, N(R2)2, o NR2 arilo; Y es un enlace covalente, CH2-, -SO2-, o >C=O ; Z es un enlace covalente, -CH2-, -SO2-, o >C=O; o Y, R1, Z y R2 pueden unirse con el átomo de nitrogeno para formar un heterocicloalquilo; con la condicion de que si Y es un enlace covalente, R1 no puede formar un enlace N-N con el átomo de nitrogeno; y n es un entero de 0 a 4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26737501P | 2001-02-08 | 2001-02-08 | |
US29260001P | 2001-05-22 | 2001-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR032569A1 true AR032569A1 (es) | 2003-11-12 |
Family
ID=26952402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020100423A AR032569A1 (es) | 2001-02-08 | 2002-02-08 | Ligandos del receptor de canabinoide |
Country Status (21)
Country | Link |
---|---|
US (2) | US7507767B2 (es) |
EP (1) | EP1368308A1 (es) |
JP (2) | JP4330341B2 (es) |
KR (1) | KR20030075175A (es) |
CN (1) | CN1285572C (es) |
AR (1) | AR032569A1 (es) |
AU (1) | AU2002306450B2 (es) |
BR (1) | BR0206955A (es) |
CA (1) | CA2436659C (es) |
CZ (1) | CZ20032122A3 (es) |
HU (1) | HUP0304060A3 (es) |
IL (1) | IL156829A0 (es) |
MX (1) | MXPA03007078A (es) |
NO (1) | NO20033505L (es) |
NZ (1) | NZ526782A (es) |
PE (1) | PE20020851A1 (es) |
PL (1) | PL364624A1 (es) |
RU (1) | RU2003127368A (es) |
SK (1) | SK9952003A3 (es) |
WO (1) | WO2002062750A1 (es) |
ZA (1) | ZA200305933B (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7067539B2 (en) * | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
CN1578663B (zh) * | 2001-09-14 | 2011-05-25 | 梅特希尔基因公司 | 组蛋白脱乙酰化酶抑制剂 |
US6897220B2 (en) * | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US7868204B2 (en) * | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
MXPA04004674A (es) | 2001-11-14 | 2004-08-12 | Schering Corp | Ligados de los receptors de los canabinodies. |
WO2003061699A1 (fr) * | 2001-12-27 | 2003-07-31 | Japan Tobacco, Inc. | Remedes pour affections allergiques |
US7217732B2 (en) * | 2002-06-19 | 2007-05-15 | Schering Corporation | Cannabinoid receptor agonists |
UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
DE60321207D1 (en) * | 2002-09-19 | 2008-07-03 | Lilly Co Eli | Diaryläther als opioid-rezeptor antagonisten |
GB0222493D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
GB0222495D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
RU2005115842A (ru) | 2002-10-24 | 2006-03-10 | Мерк Патент ГмбХ (DE) | Производные метиленмочевины |
DE60328033D1 (de) * | 2002-11-25 | 2009-07-30 | Schering Corp | Cannabinoid-rezeptorliganden |
WO2004078261A1 (en) * | 2003-03-07 | 2004-09-16 | The University Court Of The University Of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
US6916852B2 (en) * | 2003-05-12 | 2005-07-12 | University Of Tennessee Research Foundation | Method for regulation of microvascular tone |
EP1633733B1 (en) * | 2003-05-20 | 2011-01-26 | The University of Tennessee Research Foundation | Cannabinoid derivatives, methods of making, and use thereof |
JP4809228B2 (ja) * | 2003-09-24 | 2011-11-09 | メチルジーン インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
US7320805B2 (en) * | 2003-10-01 | 2008-01-22 | Institut National De La Sante Et De La Recherche Medicale | CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver |
US7390835B2 (en) * | 2003-10-30 | 2008-06-24 | Merck & Co., Inc. | Aralkyl amines as cannabinoid receptor modulators |
GB0402355D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
GB0402357D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
US7253204B2 (en) * | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
RU2387644C2 (ru) | 2004-09-30 | 2010-04-27 | Мерк Энд Ко., Инк. | Циклопропилпиперидиновые ингибиторы транспортера глицина |
WO2007070760A2 (en) | 2005-12-15 | 2007-06-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
AU2007234843B2 (en) * | 2006-04-07 | 2013-07-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
CA2657247A1 (en) | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
KR20090051778A (ko) * | 2006-09-08 | 2009-05-22 | 화이자 프로덕츠 인코포레이티드 | 다이아릴 에터 유도체 및 이의 용도 |
CN101516839A (zh) | 2006-09-25 | 2009-08-26 | 贝林格尔.英格海姆国际有限公司 | 调节cb2受体的化合物 |
GB0702862D0 (en) * | 2007-02-14 | 2007-03-28 | Univ Aberdeen | Therapeutic compounds |
AU2009296838A1 (en) | 2008-09-25 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which selectively modulate the CB2 receptor |
WO2010144394A1 (en) | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Benzyl substituted triazine derivatives and their therapeutical applications |
US9078902B2 (en) | 2009-06-09 | 2015-07-14 | Nantbioscience, Inc. | Triazine derivatives and their therapeutical applications |
CA2765053C (en) | 2009-06-09 | 2015-08-18 | California Capital Equity, Llc | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling |
JP2013517271A (ja) | 2010-01-15 | 2013-05-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節する化合物 |
WO2012012307A1 (en) | 2010-07-22 | 2012-01-26 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 rece |
US20120309820A1 (en) * | 2011-06-04 | 2012-12-06 | Jb Therapeutics Inc. | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
TW201329025A (zh) | 2011-11-01 | 2013-07-16 | Astex Therapeutics Ltd | 醫藥化合物 |
CN104136021B (zh) * | 2012-03-14 | 2016-04-20 | 中国中化股份有限公司 | 取代二苯胺类化合物作为制备抗肿瘤药物的应用 |
KR20190139327A (ko) | 2013-02-12 | 2019-12-17 | 코버스 파마수티컬스, 아이엔씨. | 초고순도 테트라하이드로카나비놀-11-오익산 |
TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
CN103265480B (zh) * | 2013-05-11 | 2015-10-07 | 浙江大学 | 喹啉二酮类衍生物及其制备方法和用途 |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US9636298B2 (en) | 2014-01-17 | 2017-05-02 | Methylgene Inc. | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs |
US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
KR102431436B1 (ko) | 2014-08-29 | 2022-08-10 | 테스 파마 에스.알.엘. | α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제 |
CN108752375A (zh) * | 2018-07-17 | 2018-11-06 | 成都睿智化学研究有限公司 | 一种4-溴甲基-2-三甲基硅乙炔基苯-1-磺酰氟的制备方法 |
CN112552200B (zh) * | 2019-09-10 | 2024-03-12 | 烟台药物研究所 | 一种光学纯4-(1-氨基)乙基苯甲酸酯及其盐的制备方法 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3715375A (en) * | 1970-09-17 | 1973-02-06 | Merck & Co Inc | New diphenyl sulfones |
US3712888A (en) * | 1970-12-14 | 1973-01-23 | American Cyanamid Co | Bis-pyridoxazole-stilbene derivatives for optical brightening |
US4170648A (en) | 1972-05-26 | 1979-10-09 | Rohm And Haas Company | Phosphonothioureide anthelmintics |
DE3039208A1 (de) | 1980-10-17 | 1982-05-13 | Basf Ag, 6700 Ludwigshafen | Neue sulfone, deren herstellung und verwendung |
DE3118126A1 (de) | 1981-05-07 | 1982-12-02 | Bayer Ag, 5090 Leverkusen | Sulfenamide zur verwendung in arzneimitteln |
US4618363A (en) | 1982-01-25 | 1986-10-21 | Ciba-Geigy Corporation | N-phenylsulfonyl-N'-triazinylureas |
US4468389A (en) | 1982-05-21 | 1984-08-28 | Rohm And Haas Company | Pesticidal N-sulfonyl phosphorodiamido(di)thioates |
US4466965A (en) | 1982-07-26 | 1984-08-21 | American Hospital Supply Corporation | Phthalazine compounds, compositions and use |
US4468965A (en) * | 1982-11-05 | 1984-09-04 | Union Carbide Corporation | Test method for acetylene cylinders |
US4567184A (en) | 1982-12-01 | 1986-01-28 | Usv Pharmaceutical Corporation | Certain aryl or hetero-aryl derivatives of 1-hydroxy-pentane or 1-hydroxy-hexane which are useful for treating inflammation and allergies |
NO174506B (no) | 1984-10-30 | 1994-02-07 | Usv Pharma Corp | Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser |
US4764889A (en) | 1984-12-19 | 1988-08-16 | American Telephone And Telegraph Company, At&T Bell Laboratories | Optical logic arrangement with self electro-optic effect devices |
US4781866A (en) | 1985-03-15 | 1988-11-01 | Mcneilab, Inc. | Process for producing amidine sulfonic acid intermediates for guanidines |
US4678855A (en) | 1985-10-09 | 1987-07-07 | Merck & Co., Inc. | Substituted benzenesulfonamides |
HU201455B (en) | 1986-03-31 | 1990-11-28 | Rhone Poulenc Bv | Synergetic compositions regulating the growth of plants |
CN1029958C (zh) | 1986-03-31 | 1995-10-11 | 联合碳化农产化学品公司 | 丙二酸衍生物阻滞植物生长的用途 |
DE3634927A1 (de) | 1986-10-14 | 1988-04-21 | Bayer Ag | Verfahren zur herstellung von sulfonylisothioharnstoffen |
DE3634926A1 (de) | 1986-10-14 | 1988-04-21 | Bayer Ag | Verfahren zur herstellung von o-aryl-n'-pyrimidin-2-yl-isoharnstoffen |
US4851423A (en) | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
CA1293516C (en) | 1987-02-10 | 1991-12-24 | Izumi Fujimoto | Benzoylurea derivative and its production and use |
NZ232493A (en) | 1989-02-14 | 1992-06-25 | Toyama Chemical Co Ltd | Aryl- or heterocyclyl-substituted 1,2-ethanediol derivatives and pharmaceutical compositions |
US5064825A (en) | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
WO1991000858A1 (en) | 1989-07-07 | 1991-01-24 | Schering Corporation | Pharmaceutically active compounds |
IT1240676B (it) | 1990-04-24 | 1993-12-17 | Agrimont Spa | Composizioni ad attivita' erbicida |
NZ239846A (en) | 1990-09-27 | 1994-11-25 | Merck & Co Inc | Sulphonamide derivatives and pharmaceutical compositions thereof |
US5332820A (en) | 1991-05-20 | 1994-07-26 | E. I. Du Pont De Nemours And Company | Dibenzobicyclo(2.2.2) octane angiotensin II antagonists |
WO1993000313A2 (en) | 1991-06-27 | 1993-01-07 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
US5506227A (en) | 1992-04-13 | 1996-04-09 | Merck Frosst Canada, Inc. | Pyridine-substituted benzyl alcohols as leukotriene antagonists |
US5338753A (en) | 1992-07-14 | 1994-08-16 | Sumner H. Burstein | (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics |
GB9218834D0 (en) | 1992-09-05 | 1992-10-21 | Procter & Gamble | Nasal spray products |
WO1995000491A1 (en) | 1993-06-17 | 1995-01-05 | Dunlena Pty Ltd. | Arthropodicidal sulfonates |
US5486525A (en) | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
BR9507106A (pt) | 1994-04-06 | 1997-11-18 | Shionogi & Co | Derivado de ácido fenilacético alfa-substituido sua produção e fungicida agricola contendo o mesmo |
IT1271266B (it) * | 1994-12-14 | 1997-05-27 | Valle Francesco Della | Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi |
CZ294097B6 (cs) | 1995-02-02 | 2004-10-13 | Smithklineábeechamáplc | Indolový derivátŹ způsob jeho přípravy a farmaceutická kompozice s jeho obsahem |
US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
US5700816A (en) | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
ES2150679T3 (es) | 1995-07-21 | 2000-12-01 | Nycomed Austria Gmbh | Derivados de bencenosulfonamidas como inhibidores de la enzima ciclooxigenasa ii. |
DE19533644A1 (de) | 1995-09-12 | 1997-03-13 | Nycomed Arzneimittel Gmbh | Neue Benzolsulfonamide |
FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
CA2245586A1 (en) | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
SE9602646D0 (sv) | 1996-07-04 | 1996-07-04 | Astra Ab | Pharmaceutically-useful compounds |
WO1998010763A1 (en) | 1996-09-13 | 1998-03-19 | Merck & Co., Inc. | Thrombin inhibitors |
JP3426890B2 (ja) | 1996-12-25 | 2003-07-14 | アルプス電気株式会社 | 入力ペン |
CA2278307A1 (en) | 1997-01-21 | 1998-07-23 | Siegfried Benjamin Christensen Iv | Novel cannabinoid receptor modulators |
ATA16597A (de) | 1997-02-03 | 1998-04-15 | Nycomed Austria Gmbh | Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide |
DE19740785A1 (de) | 1997-02-21 | 1998-08-27 | Bayer Ag | Arylsulfonamide und Analoga |
PT966436E (pt) | 1997-02-21 | 2003-03-31 | Bayer Ag | Arilsulfonamidas e analogos e sua aplicacao para o tratamento de doencas neurodegenerativas |
US5948777A (en) | 1997-03-18 | 1999-09-07 | Smithkline Beecham Corporation | Cannabinoid receptor agonists |
DE69842143D1 (de) | 1997-10-24 | 2011-04-07 | Nissan Chemical Ind Ltd | Sulfamoyl-verbindungen und bakterizide für landwirtschaft oder gartenbau |
WO1999026612A1 (en) | 1997-11-21 | 1999-06-03 | Smithkline Beecham Corporation | Novel cannabinoid receptor modulators |
EP1069111A4 (en) | 1998-03-26 | 2001-06-06 | Shionogi & Co | INDOLE DERIVATIVES EXER ANT ANTIVIRAL ACTIVITY |
HUP0102752A3 (en) | 1998-07-28 | 2002-11-28 | Smithkline Beecham Corp | Substituted anilide compounds |
JP2000143650A (ja) | 1998-11-13 | 2000-05-26 | Takeda Chem Ind Ltd | 新規チアゾリジン誘導体、その製造法および用途 |
WO2000056707A1 (en) | 1999-03-24 | 2000-09-28 | Sepracor, Inc. | Diaryl thioethers, compositions and uses thereof |
JP4618845B2 (ja) | 1999-06-09 | 2011-01-26 | 杏林製薬株式会社 | ヒトペルオキシゾーム増殖薬活性化受容体(PPAR)αアゴニストとしての置換フェニルプロピオン酸誘導体 |
US6734199B1 (en) * | 1999-08-23 | 2004-05-11 | Kyorin Pharmaceutical Co., Ltd. | Substituted benzylthiazolidine-2, 4-dione derivatives |
KR100509401B1 (ko) | 1999-09-14 | 2005-08-22 | 시오노기세이야쿠가부시키가이샤 | 2-이미노-1,3-티아진 유도체 |
AU1095101A (en) | 1999-10-18 | 2001-04-30 | University Of Connecticut, The | Cannabimimetic indole derivatives |
PT1249233E (pt) | 1999-11-26 | 2008-10-21 | Shionogi & Co | Antagonistas de y5 de npy |
AU2108601A (en) | 1999-12-15 | 2001-06-25 | Axys Pharmaceuticals, Inc. | Salicylamides as serine protease inhibitors |
EP1741713A3 (en) | 1999-12-15 | 2009-09-09 | Bristol-Myers Squibb Company | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
WO2001050824A1 (es) | 1999-12-31 | 2001-07-12 | Lear Automotive (Eeds) Spain, S.L. | Procedimiento de fabricacion de placas de circuito impreso |
WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
WO2001070753A1 (en) | 2000-03-22 | 2001-09-27 | Merck Frosst Canada & Co. | Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
AU2001253147A1 (en) | 2000-04-03 | 2001-10-15 | Phycogen, Inc. | Generation of combinatorial synthetic libraries and screening for proadhesins and nonadhesins |
AU2001258771A1 (en) | 2000-05-19 | 2001-11-26 | Takeda Chemical Industries Ltd. | -secretase inhibitors |
GB0028702D0 (en) | 2000-11-24 | 2001-01-10 | Novartis Ag | Organic compounds |
US7067539B2 (en) * | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
MXPA04004674A (es) | 2001-11-14 | 2004-08-12 | Schering Corp | Ligados de los receptors de los canabinodies. |
-
2002
- 2002-02-06 US US10/072,354 patent/US7507767B2/en not_active Expired - Fee Related
- 2002-02-07 SK SK995-2003A patent/SK9952003A3/sk unknown
- 2002-02-07 HU HU0304060A patent/HUP0304060A3/hu unknown
- 2002-02-07 CA CA2436659A patent/CA2436659C/en not_active Expired - Fee Related
- 2002-02-07 MX MXPA03007078A patent/MXPA03007078A/es active IP Right Grant
- 2002-02-07 CN CNB028043081A patent/CN1285572C/zh not_active Expired - Fee Related
- 2002-02-07 NZ NZ526782A patent/NZ526782A/en unknown
- 2002-02-07 PL PL02364624A patent/PL364624A1/xx not_active Application Discontinuation
- 2002-02-07 CZ CZ20032122A patent/CZ20032122A3/cs unknown
- 2002-02-07 JP JP2002562710A patent/JP4330341B2/ja not_active Expired - Fee Related
- 2002-02-07 RU RU2003127368/04A patent/RU2003127368A/ru not_active Application Discontinuation
- 2002-02-07 IL IL15682902A patent/IL156829A0/xx unknown
- 2002-02-07 KR KR10-2003-7010270A patent/KR20030075175A/ko not_active Application Discontinuation
- 2002-02-07 WO PCT/US2002/003672 patent/WO2002062750A1/en active IP Right Grant
- 2002-02-07 AU AU2002306450A patent/AU2002306450B2/en not_active Ceased
- 2002-02-07 EP EP02740074A patent/EP1368308A1/en not_active Withdrawn
- 2002-02-07 BR BR0206955-5A patent/BR0206955A/pt not_active IP Right Cessation
- 2002-02-08 AR ARP020100423A patent/AR032569A1/es unknown
- 2002-02-08 PE PE2002000095A patent/PE20020851A1/es not_active Application Discontinuation
-
2003
- 2003-07-31 ZA ZA2003/05933A patent/ZA200305933B/en unknown
- 2003-08-07 NO NO20033505A patent/NO20033505L/no not_active Application Discontinuation
-
2005
- 2005-08-15 US US11/203,946 patent/US7718702B2/en not_active Expired - Fee Related
-
2008
- 2008-07-17 JP JP2008186568A patent/JP2009024011A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
NO20033505D0 (no) | 2003-08-07 |
JP4330341B2 (ja) | 2009-09-16 |
CA2436659C (en) | 2010-07-27 |
IL156829A0 (en) | 2004-02-08 |
US20060009528A1 (en) | 2006-01-12 |
US7718702B2 (en) | 2010-05-18 |
RU2003127368A (ru) | 2005-03-27 |
BR0206955A (pt) | 2004-03-09 |
CA2436659A1 (en) | 2002-08-15 |
AU2002306450B2 (en) | 2005-09-22 |
PE20020851A1 (es) | 2002-12-04 |
CZ20032122A3 (cs) | 2003-10-15 |
MXPA03007078A (es) | 2003-11-18 |
EP1368308A1 (en) | 2003-12-10 |
NO20033505L (no) | 2003-10-07 |
SK9952003A3 (en) | 2004-01-08 |
HUP0304060A2 (hu) | 2004-04-28 |
PL364624A1 (en) | 2004-12-13 |
US7507767B2 (en) | 2009-03-24 |
JP2004530649A (ja) | 2004-10-07 |
CN1285572C (zh) | 2006-11-22 |
WO2002062750A9 (en) | 2003-09-18 |
KR20030075175A (ko) | 2003-09-22 |
WO2002062750A1 (en) | 2002-08-15 |
NZ526782A (en) | 2005-05-27 |
US20030096844A1 (en) | 2003-05-22 |
HUP0304060A3 (en) | 2005-05-30 |
CN1489576A (zh) | 2004-04-14 |
JP2009024011A (ja) | 2009-02-05 |
ZA200305933B (en) | 2005-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR032569A1 (es) | Ligandos del receptor de canabinoide | |
ES2528451T3 (es) | Inhibidores de esfingosina cinasa | |
AR082153A1 (es) | N-sulfonilbenzamidas utiles como inhibidor del canal de sodio | |
HRP20080113T3 (en) | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | |
AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
AR076860A1 (es) | Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
AR082152A1 (es) | Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7 | |
CO5031253A1 (es) | Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen | |
ECSP067013A (es) | 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4 | |
AR046600A1 (es) | Diazaespiroalcanos y su uso como tratamiento para enfermedades mediadas por ccr8 | |
AR030230A1 (es) | Derivados de acilfenilurea, procedimiento para su preparacion y su empleo en la preparacion de medicamentos | |
AR036093A1 (es) | Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios | |
AR071617A1 (es) | Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos. | |
AR058769A1 (es) | Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen. | |
AR077440A1 (es) | Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas | |
AR065288A1 (es) | Cmplejos cristalinos de compuestos organicos para uso agricola | |
AR049333A1 (es) | Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas. | |
JP2006509015A5 (es) | ||
PE20080067A1 (es) | DERIVADOS DE TRIAZOLOPIRAZINA COMO MODULADORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE HEPATOCITO (c-MET O HGFR) | |
AR099367A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
AR086977A1 (es) | Derivados heterociclicos nitrogenados utiles para el tratamiento del cancer y composiciones farmaceuticas que los contienen | |
AR035493A1 (es) | Derivados de azepino (4,5b) indolina sustituidos, composicion farmaceutica y el uso de dichos derivados para preparar un medicamento | |
AR043059A1 (es) | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos | |
AR046394A1 (es) | Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |